BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 24566034)

  • 1. [Venous thromboembolism and cancer].
    Meyer G
    Rev Pneumol Clin; 2014; 70(1-2):91-4. PubMed ID: 24566034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer.
    Tran QN
    Am J Hosp Palliat Care; 2010 Sep; 27(6):416-9. PubMed ID: 20197558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Risk of venous thromboembolism in cancer patients: Reality, actuality and perspectives].
    Gerotziafas GT; Elalamy I
    Bull Cancer; 2016 Sep; 103(9):764-75. PubMed ID: 27481723
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study.
    Sevestre MA; Belizna C; Durant C; Bosson JL; Vedrine L; Cajfinger F; Debourdeau P; Farge D;
    J Mal Vasc; 2014 May; 39(3):161-8. PubMed ID: 24746736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Venous thromboembolism and cancer].
    Meyer G
    Rev Prat; 2015 Feb; 65(2):216-9. PubMed ID: 25939227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment of venous thromboembolism in patients with cancer.
    Prandoni P
    Intern Emerg Med; 2010 Oct; 5 Suppl 1():S27-30. PubMed ID: 20865471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Venous thrombo-embolic disease in cancer. Low molecular weight heparin indications].
    Nou M; Laroche JP
    J Mal Vasc; 2016 May; 41(3):197-204. PubMed ID: 27146099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cancer and venous thromboembolism].
    Meyer G; Belmont L
    Rev Mal Respir; 2011 Apr; 28(4):443-52. PubMed ID: 21549900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
    Gritsiouk Y; Hegsted DA; Schlesinger P; Gardiner SK; Gubler KD
    Am J Surg; 2014 May; 207(5):648-51; discussion 651-2. PubMed ID: 24560359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cancer-associated venous thromboembolic recurrence: disregard of treatment recommendations].
    Mahé I; Chidiac J
    Bull Cancer; 2014 Mar; 101(3):295-301. PubMed ID: 24691192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice.
    Soto-Cárdenas MJ; Pelayo-García G; Rodríguez-Camacho A; Segura-Fernández E; Mogollo-Galván A; Giron-Gonzalez JA
    Palliat Med; 2008 Dec; 22(8):965-8. PubMed ID: 18952751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism.
    Marchena PJ; Nieto JA; Guil M; García-Bragado F; Rabuñal R; Boccalon H; Trujillo-Santos J; Monreal M;
    Thromb Haemost; 2012 Jan; 107(1):37-43. PubMed ID: 22116496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylaxis and treatment of venous thromboembolism in cancer patients. Clinical value of low-molecular-weight heparins].
    Kreher S; Riess H
    Internist (Berl); 2014 Apr; 55(4):448-54. PubMed ID: 24599489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment and secondary prevention of venous thromboembolism in cancer patients. Current strategies and new therapeutic options.
    Ay C; Pabinger I
    Hamostaseologie; 2012; 32(2):139-44. PubMed ID: 21822525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Risk factors for recurrent venous thromboembolism].
    Rosencher J; Mirault T; Martinez I; Zhu T; Messas E; Emmerich J
    Rev Mal Respir; 2011 Apr; 28(4):453-62. PubMed ID: 21549901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical presentation and time-course of postoperative venous thromboembolism: Results from the RIETE Registry.
    Arcelus JI; Monreal M; Caprini JA; Guisado JG; Soto MJ; Núñez MJ; Alvárez JC;
    Thromb Haemost; 2008 Mar; 99(3):546-51. PubMed ID: 18327403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry.
    Gussoni G; Frasson S; La Regina M; Di Micco P; Monreal M;
    Thromb Res; 2013 Jan; 131(1):24-30. PubMed ID: 23141849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.